Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
UTI
MCID: URN019
MIFTS: 49

Urinary Tract Infection (UTI)

Categories: Infectious diseases, Nephrological diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Urinary Tract Infection

About this section

MalaCards integrated aliases for Urinary Tract Infection:

Name: Urinary Tract Infection 12 6 17
Urinary Tract Infections 42 44
Uti 12

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:0080784
MeSH 44 D014552
ICD10 32 N39.0
Sources

Summaries for Urinary Tract Infection

About this section
MedlinePlus : 42 The urinary system is the body's drainage system for removing wastes and extra water. It includes two kidneys, two ureters, a bladder, and a urethra. Urinary tract infections (UTIs) are the second most common type of infection in the body. You may have a UTI if you notice Pain or burning when you urinate Fever, tiredness, or shakiness An urge to urinate often Pressure in your lower belly Urine that smells bad or looks cloudy or reddish Pain in your back or side below the ribs People of any age or sex can get UTIs. But about four times as many women get UTIs as men. You're also at higher risk if you have diabetes, need a tube to drain your bladder, or have a spinal cord injury. If you think you have a UTI it is important to see your doctor. Your doctor can tell if you have a UTI with a urine test. Treatment is with antibiotics. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Urinary Tract Infection, also known as urinary tract infections, is related to cystitis and pyuria. An important gene associated with Urinary Tract Infection is EBF3 (EBF Transcription Factor 3), and among its related pathways/superpathways are A-beta Pathways: Uptake and Degradation and Glyoxylate and dicarboxylate metabolism. The drugs Acetylcysteine and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include kidney, spinal cord and prostate, and related phenotypes are homeostasis/metabolism and adipose tissue

Disease Ontology : 12 An urinary system disease that is characterized by an infection in any part of the urinary system, including the kidneys, ureters, bladder or urethra.

Wikipedia : 74 A urinary tract infection (UTI) is an infection that affects part of the urinary tract. When it affects... more...

Sources

Related Diseases for Urinary Tract Infection

About this section

Diseases in the Urinary Tract Infection family:

Urinary Tract Infections, Recurrent

Diseases related to Urinary Tract Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 819)
# Related Disease Score Top Affiliating Genes
1 cystitis 32.5 UMOD TLR4 CRP
2 pyuria 32.0 LCN2 CRP
3 acute cystitis 31.9 UMOD TLR4 LCN2 CRP ACE
4 bacteriuria 31.5 UMOD TLR4 CRP CAT
5 ureteral disease 31.3 TGFB1 LCN2 ACE
6 acute pyelonephritis 31.3 LCN2 CRP ACE
7 klebsiella pneumonia 31.1 TLR4 CRP
8 pyelonephritis 31.0 UMOD TLR4 LCN2 CRP ACE
9 urethritis 31.0 TLR4 CRP
10 bacterial infectious disease 31.0 TLR4 LCN2 CRP
11 posterior urethral valves 30.9 TGFB1 ACE
12 vesicoureteral reflux 1 30.8 UMOD TGFB1 LCN2 EBF3 CRP ACE
13 neurogenic bladder 30.8 EBF3 CRP
14 microvascular complications of diabetes 3 30.7 TGFB1 ACE
15 chronic pyelonephritis 30.7 UMOD TLR4 CRP ACE
16 pneumonia 30.7 TLR4 CRP ACE
17 drug allergy 30.6 CRP ACE
18 end stage renal disease 30.5 UMOD TGFB1 CRP ACE
19 septic arthritis 30.5 TLR4 CRP
20 constipation 30.5 EBF3 CRP CAT
21 cerebrovascular disease 30.4 TLR4 CRP ACE
22 enterocolitis 30.4 TLR4 CRP
23 liver cirrhosis 30.3 TLR4 TGFB1 CRP ACE
24 acute myocarditis 30.3 CRP ACE
25 interstitial nephritis 30.3 UMOD CRP ACE
26 pulmonary disease, chronic obstructive 30.2 TGFB1 CRP ACE
27 congenital anomalies of kidney and urinary tract 2 30.2 UMOD TGFB1 LCN2
28 perinatal necrotizing enterocolitis 30.2 TLR4 CRP
29 urinary tract obstruction 30.2 UMOD TGFB1 LCN2 CRP ACE
30 optic papillitis 30.2 CRP ACE
31 prosthetic joint infection 30.2 TLR4 CRP
32 iridocyclitis 30.2 CRP ACE
33 bronchopneumonia 30.1 TLR4 CRP
34 ischemic colitis 30.1 CRP ACE
35 aspiration pneumonia 30.1 CRP ACE
36 glomerulonephritis 30.1 TGFB1 LCN2 ACE
37 coronary heart disease 1 30.1 CRP ACE
38 renal hypodysplasia/aplasia 1 30.1 UMOD EBF3 ACE
39 rapidly progressive glomerulonephritis 30.0 TGFB1 CRP
40 thrombophlebitis 30.0 TGFB1 CRP
41 respiratory failure 30.0 TLR4 CRP ACE
42 acute kidney tubular necrosis 30.0 UMOD LCN2 ACE
43 urogenital tuberculosis 30.0 CRP CAT
44 kidney disease 29.9 UMOD TGFB1 LCN2 CRP ACE
45 polycystic kidney disease 29.9 UMOD TGFB1 LCN2 ACE
46 anuria 29.9 LCN2 CRP ACE
47 portal hypertension 29.9 TLR4 TGFB1 ACE
48 urinary system disease 29.8 UMOD CRP ACE
49 pleurisy 29.8 TLR4 TGFB1 CRP
50 autosomal dominant polycystic kidney disease 29.8 TGFB1 LCN2 ACE

Graphical network of the top 20 diseases related to Urinary Tract Infection:



Diseases related to Urinary Tract Infection
Sources

Symptoms & Phenotypes for Urinary Tract Infection

About this section

MGI Mouse Phenotypes related to Urinary Tract Infection:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.76 ACE CAT CRP HOGA1 LCN2 TGFB1
2 adipose tissue MP:0005375 9.65 ACE LCN2 TGFB1 TLR4 UMOD
3 liver/biliary system MP:0005370 9.35 ACE HOGA1 LCN2 TGFB1 TLR4
4 renal/urinary system MP:0005367 9.1 ACE HOGA1 LCN2 TGFB1 TLR4 UMOD
Sources

Drugs & Therapeutics for Urinary Tract Infection

About this section

Drugs for Urinary Tract Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 364)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Lenograstim Approved, Investigational Phase 4 135968-09-1
3
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
4
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
5 Apricot Approved Phase 4
6
Cefixime Approved, Investigational Phase 4 79350-37-1 54362 5362065
7
Vancomycin Approved Phase 4 1404-90-6 441141 14969
8
Doripenem Approved, Investigational Phase 4 148016-81-3 73303
9
Sulbactam Approved Phase 4 68373-14-8
10
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
11
Zinc Approved, Investigational Phase 4 7440-66-6 32051
12
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
13
Polyestradiol phosphate Approved Phase 4 28014-46-2
14
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
15
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
16
Ibuprofen Approved Phase 4 15687-27-1 3672
17
Halofantrine Approved Phase 4 69756-53-2 37393
18
Lactitol Approved, Investigational Phase 4 585-86-4 157355
19
Sulfamethoxazole Approved Phase 4 723-46-6 5329
20
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
21
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
22
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
23
Piperacillin Approved Phase 4 66258-76-2 43672
24
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
25 Sugarcane Approved Phase 4
26
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
27
Methylene blue Approved, Investigational Phase 4 61-73-4
28
Belladonna Approved, Experimental Phase 4
29
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
30
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
31
Amikacin Approved, Investigational, Vet_approved Phase 4 37517-28-5 37768
32
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
33
Methenamine Approved, Vet_approved Phase 4 100-97-0 4101
34
Ofloxacin Approved Phase 4 82419-36-1 4583
35
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
36
Norfloxacin Approved Phase 4 70458-96-7 4539
37
Fosfomycin Approved Phase 4 23155-02-4 446987
38
Povidone-iodine Approved Phase 4 25655-41-8
39
Iodine Approved, Investigational Phase 4 7553-56-2 807
40
Povidone Approved Phase 4 9003-39-8 131751496
41
Cilastatin Approved, Investigational Phase 4 82009-34-5 5280454 6435415
42
Imipenem Approved Phase 4 64221-86-9, 74431-23-5 104838
43
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
44
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
45
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
46
Cefoxitin Approved Phase 4 35607-66-0 441199
47
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
48
Acriflavine Experimental Phase 4 65589-70-0
49
Cadexomer iodine Experimental Phase 4 94820-09-4
50 N-monoacetylcystine Phase 4

Interventional clinical trials:

(show top 50) (show all 550)
# Name Status NCT ID Phase Drugs
1 Low Dose Estriol With Lactobacilli (Gynoflor) Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized, Open, Parallel-Group Study Unknown status NCT00900653 Phase 4 Gynoflor E (low dose estriol with lactobacillus)
2 Noroxin Efficacy and Safety Trial Unknown status NCT03506256 Phase 4 Norfloxacin 400 MG
3 Randomised Clinical Trial Comparing Fosfomycin vs. Nitrofurantoin for Treatment of Uncomplicated Lower Urinary Tract Infection in Female Adults at Increased Risk of Antibiotic-resistant Bacterial Infection Unknown status NCT01966653 Phase 4 nitrofurantoin;fosfomycin
4 Granulocyte Colony Stimulating Factor Plus N-Acetyl Cysteine In Severe Alcoholic Hepatitis Unknown status NCT02971306 Phase 4 standard medical therapy;G-CSF;n-Acetylcysteine
5 An Open Label Non Placebo Study to Evaluate Efficacy and Safety of Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections Unknown status NCT03160807 Phase 4 Levofloxacin;Levofloxacin
6 A Randomised, Double-blind, Placebo Controlled Trial Evaluating the Effectiveness of a Cranberry Concentrate (CranrichTM) in Preventing Recurrent Urinary Tract Infections in Adult Women Unknown status NCT02454309 Phase 4
7 Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae Unknown status NCT02681263 Phase 4 Temocillin
8 Randomized Placebo-Controlled Trial of Gentamicin Bladder Instillation for the Prevention of Urinary Tract Infection in Adults at High Risk for Cystitis Due to Intermittent Catheterization Unknown status NCT01884467 Phase 4 Gentamicin;Placebo
9 Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a History of Upper Urinary Tract Infections:a Multicentre Randomised Study Unknown status NCT00156546 Phase 4 antibiotic to reduce the recurrence of infection
10 Comparison of the Effect of Applying Povidone-iodine and Chlorhexidine Solutions for Perinea Washing on Bacteriuria Rate and Type in Patients With Urinary Catheter in Intensive Care Unit Unknown status NCT02032394 Phase 4 Povidone-iodine;Chlorhexidine;Normal saline
11 The Impact of Antimicrobial Treatment for Asymptomatic Bacteriuria in Renal Transplant Patients Unknown status NCT02113774 Phase 4
12 The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Symptomatic Non-complicated Urinary Tract Infection in Females Unknown status NCT02094703 Phase 4 Levofloxacin;Solifenacin succinate;Placebo (for Solifenacin succinate)
13 Sanjin Tablets for the Treatment of Acute Simple Lower Urinary Tract Infection and Its Influence on Recurrence Rate: a Randomized, Double Blind, Parallel Control of Positive Drugs, Multi-center Clinical Study Unknown status NCT03658291 Phase 4 Sanjin tablets;Sanjin tablets simulants;Levofloxacin
14 A Open Multi-center Clinical Study on Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection Unknown status NCT01897831 Phase 4 xin te mie
15 The Effects of Vaginal Estrogen and a Nonhormonal Alternative on the Vaginal and Urinary Microbiome in Women With Genitourinary Syndrome of Menopause: A Randomized Controlled Trial Unknown status NCT02869165 Phase 4 Premarin vaginal cream;Apricot kernel oil
16 Temocillin Pharmacokinetics in Paediatrics Unknown status NCT02260102 Phase 4 Temocillin
17 A Randomized, Multicenter, Parallel Group Study to Evaluate Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder Completed NCT01388413 Phase 4 Weekly Oral Cyclic Antibiotic programme
18 Open Label Study on the Bacteriological and Clinical Efficacy and Safety of a Nitrofurantoin Formulation Given Twice Daily (Bid) for Seven Days in Uncomplicated Urinary Tract Infection in Adults Completed NCT01092351 Phase 4 Nitrofurantoin
19 Antibiotic Prophylaxis for Urinary Tract Infection in Patients Requiring Catheterization After Urogynecologic Surgery Completed NCT01450800 Phase 4 Nitrofurantoin;Placebo
20 Randomized Controlled Trial of Ultrasound Versus CT (Computed Tomography) for Patients in the Emergency Department With Suspected Renal Colic Completed NCT01451931 Phase 4
21 Management of Sub-Clinical Bacteriuria in Pregnancy: A Feasibility Trial Completed NCT03275623 Phase 4 Antibiotic
22 Relevance of Biomarkers and Clinical Predictors of Outcome in Unselected Population With Febrile Urinary Tract Infection at Primary Care and Emergency Department in a Prospective, Randomized Cohort Trial Comparing Short (7 Days) Antibiotic Treatment With Conventional Treatment (14 Days) Completed NCT00809913 Phase 4 short treatment (ciprofloxacin)
23 Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes Completed NCT04193566 Phase 4 Forxiga
24 Prospective, Open Label Non-comparative, Multi-center Trial to Evaluate the Efficacy and Safety of Cipro® XR 500 mg Once Daily for 3 Days in Treating Female Patients With Acute, Uncomplicated, Symptomatic Lower Urinary Tract Infections Completed NCT00669994 Phase 4 Ciprofloxacin
25 Cipro® XR Excellence in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections Completed NCT00676533 Phase 4 Cipro XR (Ciprofloxacin, BAYQ3939)
26 Recurrent Urinary Tract Infections in Children: Bacterial Identification, Antibiotic Susceptibility Profiling and Cytokine Levels Associated With Antibiotic Prophylaxis Completed NCT02357758 Phase 4 Antibiotic Prophylaxis
27 Prospective, Open-Label, Noncomparative, Multicenter Study to Evaluate the Efficacy and Safety of Ciprofloxacin Extended Release (Cipro XR) 1000 mg Tablets Given Once Daily for 7 to 14 Days in the Treatment of Patients 18 Years or Older With Complicated Urinary Tract Infections Caused by Pseudomonas Aeruginosa and Other Common Uropathogens Completed NCT00481689 Phase 4 Cipro XR (Ciprofloxacin, BAYQ3939)
28 A Randomized, Controlled, Multicentre Trial of Collateral Damage on the Intestinal Microbiota Inferred by Temocillin Versus Cefotaxime in Patients Receiving Empirical Treatment for Febrile Urinary Tract Infections Completed NCT02959957 Phase 4 Temocillin;Cefotaxime
29 Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial Completed NCT03151603 Phase 4 Arctuvan;Fosfomycin;Placebo to Arctuvan;Placebo to Fosfomycin
30 Antibiotic Prophylaxis After Acute Pyelonephritis for Prevention of Urinary Tract Infections in Children With Vesico-Ureteral Reflux. Completed NCT00382343 Phase 4 Sulfamethoxazole/trimethoprim
31 Evaluation of Suprapubic Noble Metal Alloy BIP Foley Catheter in the Prevention of Catheter-associated Urinary Tract Infections in Spinal Cord Injured Patients Completed NCT02808000 Phase 4
32 A Post Marketing Surveillance Study on the Safety and Effectiveness of Doripenem in the Therapy of Thai Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections Completed NCT00965848 Phase 4 Doripenem
33 Randomized Controlled Clinical Trial of Efficacy of Fosfomycin Versus Ciprofloxacin as Antibiotic Prophylaxis Prior to Ultrasound Guided Transrectal Prostate Biopsy Completed NCT01803191 Phase 4 Fosfomycin 3 g;Ciprofloxacin 500 mg
34 Antibiotic Treatment for Intermittent Bladder Catheterisation: A Randomised Controlled Trial of Once Daily Prophylaxis Completed NCT02145338 Phase 4 Nitrofurantoin or Trimethoprim or Cefalexin
35 EXPRESS: Evaluating Cipro XR Patient Response, Education, Safety, and Satisfaction Completed NCT00663806 Phase 4
36 Methenamine Hippurate Versus Trimethoprim in the Prevention of Recurrent UTIs Completed NCT03077711 Phase 4 Trimethoprim;Methenamine hippurate
37 Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Infection: A Randomized Controlled Study Completed NCT03099863 Phase 4 Cystoscopic Fluid containing Neosporin G. U. Irrigant;Cystoscopic Fluid/Placebo
38 Use of Standardized Delegation Form in Diagnosing and Treating Acute Cystitis in Primary Care Facilities. Completed NCT01132131 Phase 4
39 Pharmacokinetics of Ciprofloxacin in Pediatric Patients With Emphasis on Renal Excretion Completed NCT02598362 Phase 4 ciprofloxacin
40 Fosfomycin-Trometamol in Urinary Tract Infection Prophylaxis After Kidney Transplantation. Randomized Controlled Trial. Completed NCT01820897 Phase 4 Fosfomycin-Trometamol;Sulfamethoxazole trimethoprim
41 Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized Clinical Trial Completed NCT01958073 Phase 4 Conjugated Estrogen Vaginal Cream;Estradiol Ring;Placebo
42 Use of Antibiotic Prophylaxis on Urethral Catheter Withdrawal: A Randomized Double-Blind Placebo-Controlled Trial Completed NCT00126698 Phase 4 trimethoprim-sulfamethoxazole;ciprofloxacin
43 Immediate vs. Conditional Use of Antibiotics in Uncomplicated Urinary Tract Infection (UTI) - a Comparative Effectiveness Study in General Practice (ICUTI) Completed NCT01488955 Phase 4 Ibuprofen;Fosfomycin-Trometamol
44 Perioperative Disodium Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients. Controlled Clinical Trial (PERIFOS Trial) Completed NCT03235947 Phase 4 Fosfomycin disodium;Trimethoprim / Sulfamethoxazole;Intravenous placebo
45 Randomized Controled Multicentric Trial, of Non Inferiority, Comparing Two Durations of Antibiotherapy (5 Days Versus 10 Days) in COMMUNAUTARY Acute Uncomplicated Pyelonephritis. Completed NCT00873626 Phase 4 levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)
46 Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery (NAUTICA): A Randomized Controlled Trial Completed NCT03287089 Phase 4 Nitrofurantoin 100 MG;Placebo Oral Tablet
47 Clinical and Microbiologic Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection in Adult Women. Completed NCT03366207 Phase 4 Ciprofloxacin
48 Introduction of Nitrofurantoin in Place of Ciprofloxacin in Patients of Uncomplicated Urinary Tract Infection: a Controlled Clinical Trial to Establish the Relationship Between Revival and Associated Shift in Sensitivity Pattern of the Causative Microbes Completed NCT03716804 Phase 4 Tablet Nitrofurantoin;Tablet Ciprofloxacin/ Tablet Cefixime/ Tablet Cefuroxime
49 The Bacteriuria in Renal Transplantation (BiRT) Study: A Prospective, Randomized, Parallel-group, Multicenter, Open-label, Superiority Trial Comparing Antibiotics Versus no Treatment in the Prevention of Symptomatic Urinary Tract Infection in Kidney Transplant Recipients With Asymptomatic Bacteriuria Completed NCT01871753 Phase 4
50 Does Prophylaxis With Macrobid Reduce the Incidence of Urinary Tract Infection in Patients Who Receive a Sub-Urethral Sling for the Treatment of Stress Urinary Incontinence: Randomized, Double Blinded Placebo Controlled Clinical Trial Completed NCT00734968 Phase 4 Nitrofurantoin

Search NIH Clinical Center for Urinary Tract Infection

Cochrane evidence based reviews: urinary tract infections

Sources

Genetic Tests for Urinary Tract Infection

About this section
Sources

Anatomical Context for Urinary Tract Infection

About this section

MalaCards organs/tissues related to Urinary Tract Infection:

40
Kidney, Spinal Cord, Prostate, Neutrophil, Liver, Skin, Heart
Sources

Publications for Urinary Tract Infection

About this section

Articles related to Urinary Tract Infection:

(show top 50) (show all 41364)
# Title Authors PMID Year
1
Emergence of Extended-Spectrum β-Lactamase Urinary Tract Infections Among Hospitalized Emergency Department Patients in the United States. 42 61
33131912 2021
2
Impact of sodium-glucose cotransporter-2 inhibitors-induced glucosuria in the incidence of urogenital infection on postmenopausal women with diabetes. 61 42
33016178 2020
3
Taking care of continence patients during the COVID-19 pandemic. 42
33325293 2020
4
A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infection. 61
33331182 2021
5
Genomic and phenotypic analyses of multidrug-resistant Acinetobacter baumannii NCCP 16007 isolated from a patient with a urinary tract infection. 61
33372826 2021
6
Phylogenetic Group B2 Expressed Significant Biofilm Formation among Drug Resistant Uropathogenic Escherichia coli. 61
33170767 2021
7
Clinical profile of a Polish cohort of children and young adults with cystinuria. 61
33349102 2021
8
Isolation, characterization and antibiotic resistance of Proteus mirabilis from Belgian broiler carcasses at retail and human stool. 61
33494897 2021
9
Hydronephrosis caused by kidney malrotation. 61
33489770 2021
10
A phase 3, randomized, controlled trial of Astodrimer 1% Gel for preventing recurrent bacterial vaginosis. 61
33537666 2021
11
Biocompatibility and stability during storage of Foley urinary catheters coated chlorhexidine loaded nanoparticles by nanocoating: in vitro and in vivo evaluation. 61
32918382 2021
12
Intravesical acetic acid in combination with prophylactic methenamine and ascorbic acid to decrease the incidence of recurrent urinary tract infections associated with intermittent urinary self-catherization: A case report. 61
33365254 2021
13
Efficacy of the modified Frailty Index and the modified Charlson Comorbidity Index in predicting complications in patients undergoing operative management of proximal humerus fracture. 61
32650081 2021
14
Perceptions of a Nurse-Driven Urinary Catheter Removal Protocol in a Hospital Setting. 61
33534249 2021
15
The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. 61
32940121 2021
16
Use of procalcitonin and C-reactive protein in the diagnosis of bacterial infection in infants with severe bronchiolitis. 61
32929531 2021
17
Paediatric Escherichia coli bacteraemia presentations and high-risk factors in the emergency department. 61
32815584 2021
18
Active Surveillance of Healthcare-associated Infections in Pediatric Intensive Care Units: Multicenter ECDC HAI-net ICU Protocol (v2.2) Implementation, Antimicrobial Resistance and Challenges. 61
33565812 2021
19
Acute kidney injury in patients hospitalized with febrile urinary tract infections: A prospective observational study. 61
33355088 2021
20
Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. 61
33026903 2021
21
Hemolysis due to Alpha-Hemolytic Enterococcus Urinary Infection: A Rare Cause of Early and Severe Unconjugated Hyperbilirubinemia in a Neonate. 61
33585066 2021
22
Purple urine bag syndrome:A simple and rare spot diagnosis in Uroscopic rainbow. 61
33384931 2021
23
The microbiome in urinary tract infections in children - an update. 61
33449574 2021
24
The FOCCUS study: a prospective evaluation of the frequency, severity and treatable causes of gastrointestinal symptoms during and after chemotherapy. 61
32676853 2021
25
Swiss consensus recommendations on urinary tract infections in children. 61
32621135 2021
26
Management of Urologic Conditions in Small Ruminants. 61
33358314 2021
27
Recurrent urinary tract infection and nephrocalcinosis: Answers. 61
32577805 2021
28
Recurrent urinary tract infection and nephrocalcinosis: Questions. 61
32577806 2021
29
Urinary Tract Infection after Elective Spine Surgery: Timing, Predictive Factors, and Outcomes. 61
33534444 2021
30
Hyponatremia in childhood urinary tract infection. 61
32949290 2021
31
Iron Deficiency Anemia is Associated with Increased Early Postoperative Surgical and Medical Complications Following Total Hip Arthroplasty. 61
33067093 2021
32
Study Protocol: Seven vs. 14 days treatment for afebrile men with urinary tract infection. 61
33521380 2021
33
Renal agenesis associated with contralateral ectopic ureter and hydroureteronephrosis. 61
33363676 2021
34
Sex effects in pyelonephritis. 61
32040629 2021
35
Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. 61
33389263 2021
36
Does Symptomatic Benign Prostatic Hyperplasia Increase the Risk of Periprosthetic Joint Infection After Primary Total Joint Arthroplasty? 61
33032874 2021
37
Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study. 61
33236515 2021
38
Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. 61
33495295 2021
39
Recurrent neurosurgical site infection by extensively drug-resistant P. aeruginosa treated with cefiderocol: a case report and literature review. 61
33295821 2021
40
Correction to: Swiss consensus recommendations on urinary tract infections in children. 61
33001233 2021
41
Procalcitonin as a predictor of early antibiotic treatment failure in patients with gram-negative bloodstream infections caused by urinary tract infections. 61
33220639 2021
42
Polysaccharides extract from Vaccaria segetalis seeds inhibits kidney infection by regulating cathelicidin expression. 61
33141055 2021
43
A Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Sitagliptin in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control on Ipragliflozin. 61
33565686 2021
44
Prevention of urinary infection through the incorporation of silver-ricinoleic acid-polystyrene nanoparticles on the catheter surface. 61
33530824 2021
45
Glucocorticoid maintenance therapy and severe infectious complications in ANCA-associated vasculitis: a retrospective analysis. 61
33222006 2021
46
Effect of Pudendal Blockade on Bladder Emptying After Midurethral Sling: A Randomized Controlled Trial. 61
33009265 2021
47
Risk Factors for Intraoperative Bladder Perforation at the Time of Midurethral Sling Placement. 61
33227306 2021
48
Current spectrum of causative pathogens in sepsis: A prospective nationwide cohort study in Japan. 61
33221519 2021
49
Relationships between predischarge and postdischarge infectious complications, length of stay, and unplanned readmissions in the ACS NSQIP database. 61
32933745 2021
50
Warmer Weather and the Risk of Urinary Tract Infections in Women. 61
32945727 2021
Sources

Variations for Urinary Tract Infection

About this section

ClinVar genetic disease variations for Urinary Tract Infection:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 EBF3 NM_001005463.3(EBF3):c.280_283del (p.Glu94fs) Deletion Pathogenic 375502 rs1057519521 10:131761639-131761642 10:129963375-129963378
Sources

Expression for Urinary Tract Infection

About this section
Search GEO for disease gene expression data for Urinary Tract Infection.
Sources

Pathways for Urinary Tract Infection

About this section

Pathways related to Urinary Tract Infection according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
A-beta Pathways: Uptake and Degradation 64
10.46 TLR4 ACE
2
Glyoxylate and dicarboxylate metabolism 36
10.1 HOGA1 CAT
Sources

GO Terms for Urinary Tract Infection

About this section

Cellular components related to Urinary Tract Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.43 UMOD TGFB1 LCN2 CRP CAT ACE
2 extracellular space GO:0005615 9.1 UMOD TGFB1 LCN2 CRP CAT ACE

Biological processes related to Urinary Tract Infection according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.62 TLR4 TGFB1 LCN2 CRP
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.54 TLR4 TGFB1 CAT
3 ureteric bud development GO:0001657 9.49 TGFB1 CAT
4 lipopolysaccharide-mediated signaling pathway GO:0031663 9.48 TLR4 TGFB1
5 response to radiation GO:0009314 9.46 TGFB1 CAT
6 inflammatory response GO:0006954 9.46 UMOD TLR4 TGFB1 CRP
7 negative regulation of interleukin-17 production GO:0032700 9.43 TLR4 TGFB1
8 kidney development GO:0001822 9.43 UMOD CAT ACE
9 positive regulation of superoxide anion generation GO:0032930 9.4 TGFB1 CRP
10 response to drug GO:0042493 9.26 UMOD TGFB1 LCN2 CAT
11 mononuclear cell proliferation GO:0032943 8.62 TGFB1 ACE

Molecular functions related to Urinary Tract Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.02 TLR4 TGFB1 LCN2 CRP CAT
Sources

Sources for Urinary Tract Infection

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....